Group 1 - In the first eight months of the year, 610 out of 644 comparable QDII funds saw an increase in net value, representing 94.7% of the total [1] - The innovative drug sector has rebounded, leading to significant gains for funds heavily invested in this area, with top performers including Huatai-PB Hong Kong Advantage Selected Mixed C and A, achieving returns of 133.73% and 133.56% respectively [1] - The top ten holdings of Huatai-PB Hong Kong Advantage Selected Mixed A/C include companies such as InnoCare Pharma, Kelun-Biotech, and Innovent Biologics [1] Group 2 - Ten QDII funds recorded gains exceeding 90%, with four from E Fund Management, including E Fund Global Pharmaceutical Industry Mixed Fund, all surpassing 94% [2] - The top ten holdings of these E Fund products include major players like Innovent Biologics and InnoCare Pharma [2] Group 3 - Funds such as GF CSI Hong Kong Innovative Drug ETF and Huatai-PB Hang Seng Innovative Drug ETF also performed well, with returns of 103.70% and 100.04% respectively [3] - The top ten holdings of the larger Huatai-PB Hang Seng Biotechnology ETF include companies like Innovent Biologics and WuXi Biologics [3] Group 4 - The bottom performers among QDII funds primarily tracked the FTSE Saudi Arabia Index, with several oil and gas funds and those tracking the S&P 500 healthcare index also underperforming [4]

中国经济网北京8月7日讯（记者 何潇） 今年前7个月，全市场650只（各类份额分开计算，下同）有可 比业绩的QDII基金中，共有600只基金净值上涨，占比92.31%；有49只基金净值下跌；其余1只基金净 值持平。 以工银新经济混合美元、工银新经济混合人民币为例，截至二季度末，该基金的前十大重仓股为科伦博 泰生、信达生物、三生制药、海思科（002653）、药明康德（603259）、恒瑞医药（600276）、再鼎医 药、百济神州、先声药业、翰森制药。目前由基金经理赵蓓管理。赵蓓2010年加入工银瑞信，现任研究 部副总监、医疗保健研究团队负责人。 跌幅榜上，前7个月垫底QDII基金的主要为跟踪富时沙特阿拉伯指数的的产品。此外，一些跟踪标普 500医疗保健等权重指数、标普生物科技精选行业指数的QDII基金以及原油、油气类基金也表现欠佳。 汇添富香港优势精选混合A/C在今年二季度持续聚焦在创新药、优秀设备耗材龙头方向。截至二季度末 其前十大重仓股分别为映恩生物、科伦博泰生、信达生物、和黄医药、康诺亚、三生制药、诺诚健华、 石药集团、康方生物、荣昌生物。 该基金的现任基金经理为张韡。张韡曾任东方证券医药助理研究员，汇添 ...

Group 1 - In July 2023, 670 comparable QDII funds were analyzed, with 586 funds (87.46%) showing an increase in net value, while 80 funds experienced a decline, and 4 funds remained flat [1] - 15 QDII funds had a monthly increase exceeding 24%, with the top performers being E Fund Global Healthcare Mixed Fund (QDII) C (USD) at 28.94%, followed closely by other E Fund variants [1] - The E Fund Global Healthcare Mixed Fund (QDII) C (USD) was established on November 15, 2023, while its A share (USD) was launched on January 20, 2020 [1] Group 2 - As of July 31, 2025, the year-to-date returns for the top E Fund variants were 97.18%, 96.71%, 96.05%, and 95.63%, with cumulative net values ranging from 0.1956 to 1.4089 [2] - The fund maintained a positive outlook on the Chinese pharmaceutical industry, particularly focusing on innovative drug companies, and optimized stock selection as of the second quarter [2] - The largest fund by size among the top performers was the GF CSI Hong Kong Innovative Drug ETF, with a scale of 15.9 billion yuan and a July increase of 27.04% [2] Group 3 - The Manulife India Equity Fund (QDII), established on January 30, 2019, reported a year-to-date return of -2.38% and a cumulative net value of 1.5203 yuan as of July 31, 2025 [3] - The fund's investment strategy shifted from strong defensive positions to include more mid-cap companies and sectors like public utilities and new consumption [3] - The top ten holdings of the Manulife India Equity Fund included major companies such as Reliance Industries and HDFC Bank as of the second quarter [3]

成立近17年来，华夏香港一直致力于打造一个差异化的中资机构。 金融产品创新，如同"拿着锤子找钉子"，也如同"找准钉子造锤子"的过程。这意味着开拓者要兼具前瞻 视野以定位潜在需求，以及拆解难点、构建创新动能的能力。华夏基金（香港）近年来正是如此践行： 放弃"寻找更好的蜡烛"，选择"点亮电灯"，在新兴赛道上持续破局。 在华夏香港CEO甘添看来，新技术革命对金融业并非锦上添花，而是形态重塑。正如十几年前，在没人 可以想象互联网将以全天候、跨地域、效率革命的线上业态颠覆大众消费习惯时，就有一批科技企业致 力于创新产品改变生活。当下中国香港市场的创新土壤，为资管机构提供了不可多得的战略机遇。华夏 香港作为创新的笃行者，在拥有全面资产类别的背景下，每一阶段性的战略方向都充满前瞻性，打造了 多只全球首发、亚洲首发、中国香港市场首发的产品。 甘添看好离岸人民币债券市场未来三到五年的爆发式增长，华夏香港已抢占布局先机：香港首只以人民 币计价、跨市场、纯投资级别的人民币债券公募基金正是来自华夏香港。甘添预测，离岸人民币资金池 有望在2030年达约5万亿元规模，而点心债（离岸人民币债券）作为核心载体面临历史性机遇。 甘添，华夏基金 ...

Core Viewpoint - 华夏基金（香港） is positioning itself as a differentiated Chinese financial institution, focusing on innovative financial products and capitalizing on emerging market opportunities, particularly in the offshore RMB bond market [1][3][7]. Group 1: Company Strategy and Innovation - 华夏基金（香港） has adopted a forward-looking approach, launching several innovative products, including the first RMB-denominated public fund in Hong Kong, which targets investment-grade bonds [3][7]. - The company has successfully launched the largest offshore RMB money market ETF globally, with a scale of 4.97 billion RMB, demonstrating its ability to identify and capitalize on market trends [3][4]. - The firm has also introduced the first pure Hong Kong stock biotechnology ETF, which has gained significant traction among both domestic and international investors [4][5]. Group 2: Market Outlook and Growth Potential - 甘添, CEO of 华夏基金（香港）, predicts explosive growth in the offshore RMB bond market over the next three to five years, with the offshore RMB fund pool expected to reach approximately 5 trillion RMB by 2030 [1][7]. - The point bond market has seen substantial growth, with its scale increasing from 254 billion RMB in 2020 to nearly 1 trillion RMB currently, driven by attractive yields compared to domestic bonds [8][9]. - The company anticipates that the increasing participation of domestic institutions in the offshore RMB market will be fueled by favorable policies and the growing appeal of point bonds [9][10]. Group 3: Regulatory and Market Dynamics - The Chinese government is actively supporting the internationalization of the RMB, which is expected to enhance the development of the offshore RMB market and create a stable liquidity supply channel [7][9]. - Recent policy changes, such as the relaxation of cross-border investment channels, are expected to facilitate domestic investors' access to offshore RMB assets, further boosting market growth [9][10]. - The shift in the Hong Kong stock market's pricing power, with increasing domestic investment, indicates a changing landscape where local investors are becoming more influential [10][11].

Core Viewpoint - 华夏基金（香港） is positioning itself as a differentiated Chinese financial institution, focusing on innovative financial products and capitalizing on emerging market opportunities [1][2]. Group 1: Innovation and Market Positioning - 华夏香港 has adopted a forward-looking approach, launching several first-of-their-kind financial products in the Hong Kong market, including the first RMB-denominated public fund and the largest offshore RMB money market ETF [2][3]. - The company has successfully identified and capitalized on market trends, such as the growth of the offshore RMB bond market, by launching products like the 华夏精选人民币投资级别收益基金 during a period of currency volatility [2][3]. Group 2: Offshore RMB Bond Market - 甘添 predicts explosive growth in the offshore RMB bond market over the next three to five years, with the offshore RMB fund pool expected to reach approximately 5 trillion by 2030 [2][5]. - The point bond market has seen significant growth, with its scale increasing from 2.54 trillion in 2020 to nearly 10 trillion currently, driven by a decrease in RMB financing costs [6][7]. Group 3: Investment Opportunities - The point bond market offers attractive yields compared to domestic bonds, with yields for similar maturity bonds being 30-50 basis points higher than their domestic counterparts [6][7]. - Major domestic enterprises are increasingly participating in the point bond market, with significant issuances from companies like 百度 and 蒙牛乳业, indicating strong market demand [7][8]. Group 4: Market Dynamics and Future Outlook - The influx of domestic capital into the Hong Kong stock market is shifting the pricing power, with local investors now holding a significant portion of shares [8]. - The anticipated introduction of a mechanism allowing mainland investors to directly invest in Hong Kong stocks using offshore RMB is expected to enhance participation and pricing power in the market [8].

Group 1 - The core viewpoint of the report indicates that the construction materials and coal industries performed well during the period, with the Shanghai Composite Index rising by 1.67% and the Shenzhen Component Index increasing by 2.33% [2][9] - In the recent 12 periods, the comprehensive and pharmaceutical industries showed strong performance, suggesting potential investment opportunities in these sectors [9] - Active equity funds focusing on electronics and coal industries also demonstrated superior performance during this period [14] Group 2 - Among various fund types, actively managed stock funds increased by 1.55%, while mixed funds rose by 1.63%, and bond funds saw a slight decline of 0.16% [2] - The average return of convertible bond funds was notably high at 12.46% year-to-date, indicating a strong performance in this category [17] - QDII funds, particularly those focused on Asia-Pacific and emerging markets, led the performance with an increase of 2.56% during the period [19][21]

Core Viewpoint - The ETF performance in the first half of 2025 shows a stark contrast, with the Hong Kong innovative drug ETFs surging over 58%, while the photovoltaic industry ETFs faced a decline of over 11% [2][3]. Group 1: Performance of Innovative Drug ETFs - The top-performing ETFs are dominated by the pharmaceutical sector, particularly focusing on Hong Kong innovative drugs and biotechnology, indicating strong investor interest in the innovative drug field [3]. - The leading ETF, Huatai-PB Hong Kong Innovative Drug ETF, achieved a remarkable increase of 58.77%, with a scale of 7.802 billion [4]. - Other notable ETFs include Yinhua and Wanji's Hong Kong Innovative Drug ETFs, both exceeding 57% growth, showcasing significant capital involvement in the sector [4][5]. Group 2: Performance of Photovoltaic and Traditional Energy ETFs - In stark contrast, the coal and photovoltaic industry ETFs experienced significant declines, with the top loser, Guotai Zhongzheng Coal ETF, dropping by 12.28% [6][7]. - The photovoltaic ETFs collectively faced severe downturns, with all listed ETFs in this category recording declines exceeding 11%, reflecting the industry's adjustment pressures [7][8]. Group 3: Underlying Market Dynamics - The extreme market divergence reflects a sensitive response to changes in industry trends, driven by supportive policies for innovative drugs and the challenges faced by traditional energy and photovoltaic sectors [9]. - Recent policies from various government departments have provided robust support for the innovative drug industry, enhancing its development prospects [9][10]. - Conversely, the photovoltaic sector is grappling with overcapacity and financial losses, with expectations for a prolonged adjustment period before recovery [10]. Group 4: Future Outlook - The innovative drug market in China is projected to have significant growth potential, driven by low per capita medical spending and an aging population [11]. - The Hong Kong innovative drug sector is expected to continue its rapid development, supported by policy initiatives and advancements in research and commercialization [11][12]. - Long-term perspectives suggest that innovative drugs represent a "long slope, thick snow" sector, emphasizing the importance of distinguishing between thematic speculation and value growth [12].

Group 1 - The average net value of QDII funds increased by 13.19% in the first half of the year, with significant performance from Hong Kong innovative drug sector funds, many of which saw net value increases exceeding 40% [1] - The top-performing QDII fund, Huatai-PB Hang Seng Innovation Drug ETF, achieved a remarkable 93.49% increase, followed by several other funds with gains over 50% [1] - QDII products related to European stock markets and gold also performed well, with net value increases surpassing 20% for funds like Huaan Germany DAX ETF and Jiashe Gold [1] Group 2 - Oil-related QDII funds experienced significant volatility in returns this year, with Brent crude oil prices dropping below $60 per barrel in April due to OPEC production increases and weak demand [2] - Following recent geopolitical tensions, international oil prices have rebounded, leading to a recovery in the returns of oil-related QDII funds, with Jiashe Oil seeing a 12.14% increase in net value since June [2] - Other oil-related ETFs, such as the Fuguo S&P Oil and Gas Exploration and Production Select Industry ETF, also reported net value increases exceeding 5% [2]

Core Viewpoint - The QDII funds have shown remarkable performance in the first half of 2025, with equity products achieving net value growth rates close to 90%, driven by strong rebounds in the Hong Kong stock market, particularly in sectors like innovative drugs, new consumption, and technology [1][2]. QDII Fund Performance - As of June 26, 2025, the average net value growth rate of 312 equity QDII funds was 12.5%, with top performers primarily in the innovative drug and biopharmaceutical sectors [3]. - The fund managed by Zhang Wei, Huatai-PB Hong Kong Advantage Selection A, led the market with a net value growth rate of 89.15% [3]. - Other notable funds include Huatai-PB Hang Seng Innovative Drug ETF and GF CSI Hong Kong Innovative Drug ETF, both exceeding 54% growth [3]. Market Drivers - The strong performance of QDII funds is attributed to the robust performance of the Chinese market, particularly the significant rise in stock prices of Hong Kong internet technology companies [3]. - The Chinese macroeconomic landscape has shown signs of stabilization, with no significant negative impacts from tariff policies, and a trend of upward reversal in the fundamentals of the technology sector [3][4]. Investment Opportunities - Looking ahead to the second half of 2025, there are significant investment opportunities in Hong Kong stocks, especially in leading companies within the internet, innovative drugs, and new consumption sectors [5][6]. - The Hong Kong stock market is seen as being in a value recovery phase, with many high-quality companies successfully expanding globally, which has not yet been fully priced in [6]. Sector Focus - The technology sector in Hong Kong is highlighted as a key area for investment, driven by the macroeconomic narrative of asset revaluation and the rise of the Chinese technology industry [7]. - The Hang Seng Technology Index is characterized by low valuations and high growth potential, with expectations of strong earnings growth for its constituent companies [8]. Global Market Insights - There is a positive outlook for the US stock market, particularly in the technology sector, supported by a clearer shift in monetary policy and favorable fiscal signals [8][9]. - Key factors for the US market include anticipated interest rate cuts, easing financial regulations, and a manageable risk environment in the bond market [8][9]. Regional Opportunities - Investment managers are focusing on three main areas for the second half: the US technology sector, gold as a hedge against geopolitical changes and a weakening dollar, and regional opportunities in East and Southeast Asia [9].